Advertisement

Marker Therapeutics, Inc. MRKR

Set alert

Price alert · MRKR

All alert types
0.98 USD -0.03 -2.97%

At close · Oct 30

0.98 0.00 0.00%

After hours · Oct 30, 4:00 PM ET

Bid
0.97 × 6
Ask
1.00 × 6
0.9656 Day range 1.04
0.86 52-week range 2.19
YTD
-34.23%
1 year
-1.01%
Open
1.03
Prev close
1.01
Mkt cap
16.34M
Vol
67.56K
Avg vol
108.06K
EPS
-0.42
P/E
0.00
Div yield
0.00%
More statistics
Low
0.9656
High
1.04
Forward P/E
-2.34
Beta
1.49
Short ratio
1.55
Inst. own
22.44%
Dividend
0.00
Ex-div date
Earnings
Mar 27, 2024
50-d avg
3.71
200-d avg
3.97
1y target
19.00

2Y chart

Chart tools
Interval

Events in this range
  • Nov 14, 2024Earnings: -0.26; estimate 0; surprise —%
Signals (89)
NameDateAgo
MACD: Buy SignalOct 28, 20263 days ago
MACD: Sell SignalOct 27, 20264 days ago
SMA: BearishOct 20, 20261 week ago
SMA: BullishOct 19, 20261 week ago
MACD: Buy SignalOct 19, 20261 week ago
MACD: Sell SignalSep 25, 20261 month ago
MACD: Buy SignalSep 23, 20261 month ago
MACD: Sell SignalSep 3, 20261 month ago
SMA: BearishSep 1, 20262 months ago
SMA: BearishAug 28, 20262 months ago
SMA: BullishAug 24, 20262 months ago
SMA: BullishAug 21, 20262 months ago
MACD: Buy SignalAug 12, 20262 months ago
RSI: OversoldJul 29, 20263 months ago
SMA: BearishJul 16, 20263 months ago
MACD: Sell SignalJul 15, 20263 months ago
RSI: OverboughtJul 7, 20263 months ago
SMA: BullishJun 29, 20264 months ago
SMA: BullishJun 29, 20264 months ago
MACD: Buy SignalJun 29, 20264 months ago
SMA: BearishJun 24, 20264 months ago
SMA: BullishJun 22, 20264 months ago
SMA: BearishJun 18, 20264 months ago
MACD: Sell SignalJun 9, 20264 months ago
SMA: BearishJun 2, 20265 months ago
MACD: Buy SignalMay 27, 20265 months ago
SMA: BearishMay 15, 20265 months ago
SMA: BullishMay 14, 20265 months ago
MACD: Sell SignalApr 23, 20266 months ago
RSI: OverboughtApr 9, 20266 months ago
SMA: BearishMar 27, 20267 months ago
SMA: BullishMar 25, 20267 months ago
MACD: Buy SignalMar 25, 20267 months ago
MACD: Sell SignalMar 23, 20267 months ago
MACD: Buy SignalMar 20, 20267 months ago
MACD: Sell SignalMar 18, 20267 months ago
MACD: Buy SignalMar 17, 20267 months ago
SMA: BullishMar 16, 20267 months ago
SMA: BearishMar 13, 20267 months ago
MACD: Sell SignalMar 2, 20268 months ago
MACD: Buy SignalFeb 26, 20268 months ago
SMA: BearishFeb 9, 20268 months ago
MACD: Sell SignalJan 26, 20269 months ago
MACD: Buy SignalJan 20, 20269 months ago
MACD: Sell SignalJan 15, 20269 months ago
RSI: OverboughtJan 5, 20269 months ago
MACD: Buy SignalDec 29, 202510 months ago
MACD: Sell SignalDec 17, 202510 months ago
RSI: OverboughtDec 9, 202510 months ago
RSI: OverboughtDec 4, 202511 months ago
SMA: BullishDec 3, 202511 months ago
SMA: BearishDec 1, 202511 months ago
SMA: BullishNov 28, 202511 months ago
SMA: BullishNov 18, 202511 months ago
MACD: Buy SignalNov 18, 202511 months ago
SMA: BearishNov 11, 202511 months ago
SMA: BullishNov 10, 202511 months ago
SMA: BearishNov 3, 202512 months ago
SMA: BullishOct 30, 20251 year ago
SMA: BearishOct 29, 20251 year ago
MACD: Sell SignalOct 29, 20251 year ago
SMA: BullishOct 24, 20251 year ago
SMA: BearishOct 22, 20251 year ago
SMA: BullishOct 14, 20251 year ago
SMA: BullishOct 6, 20251 year ago
MACD: Buy SignalSep 11, 20251 year ago
RSI: OversoldSep 3, 20251 year ago
RSI: OversoldAug 28, 20251 year ago
MACD: Sell SignalAug 26, 20251 year ago
MACD: Buy SignalAug 22, 20251 year ago
SMA: BearishJul 29, 20251 year ago
MACD: Sell SignalJul 21, 20251 year ago
MACD: Buy SignalJul 17, 20251 year ago
MACD: Sell SignalJul 15, 20251 year ago
MACD: Buy SignalJul 9, 20251 year ago
MACD: Sell SignalJun 17, 20251 year ago
RSI: OverboughtJun 11, 20251 year ago
RSI: OverboughtJun 6, 20251 year ago
RSI: OverboughtMay 30, 20251 year ago
SMA: BullishMay 29, 20251 year ago
MACD: Buy SignalMay 23, 20251 year ago
MACD: Sell SignalMay 14, 20251 year ago
SMA: BearishMay 9, 20251 year ago
SMA: BullishMay 8, 20251 year ago
MACD: Buy SignalApr 9, 20251 year ago
MACD: Sell SignalApr 7, 20251 year ago
MACD: Buy SignalFeb 5, 20251 year ago
RSI: OversoldJan 21, 20251 year ago
MACD: Sell SignalDec 24, 20241 year ago

Key statistics

Market cap
30.52M
Enterprise value
19.59M
Trailing P/E
0.00
Forward P/E
-2.34
PEG ratio
0.00
Price / sales
8.19
Price / book
2.16
EPS (TTM)
-1.07
Beta
1.49
Dividend yield
0.00%
Payout ratio
0.00%
Profit margin
-278.22%
Revenue (TTM)
3.73M
Revenue growth
53.30%
Free cash flow
-7.40M
Total cash
7.80M
Total debt
0
Return on equity
-71.74%
Shares outstanding
8.92M
Short % of float
1.09%
50-day average
3.71
200-day average
3.97

Analyst view

Consensus: strong buy

Strong buy
Price target (mean) 19.00
Ratings (0m) 1 1 buy · 0 hold · 0 sell
  • Strong buy0
  • Buy1
  • Hold0
  • Sell0
  • Strong sell0

Next earnings

Mar 27, 2024

Expected Mar 27, 2024. Consensus EPS estimate -0.28.

Earnings history

Financials — quick view

All financials
MRKR Revenue — quarterly 0
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026
MRKR Net income — quarterly -1.83M
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026
MRKR EPS — quarterly -0.09
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026

Earnings

MRKR recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Nov 14, 2024Sep 1, 20240.00-0.26——
Aug 14, 2024Jun 1, 20240.00-0.25——
May 15, 2024Mar 1, 20240.00-0.27——
Mar 27, 2024Dec 1, 20230.00———
Nov 9, 2023Sep 1, 20230.00-0.34——
Aug 14, 2023Jun 1, 20230.00-0.47——

Upgrades / downgrades

MRKR analyst upgrades and downgrades
DateFirmActionFromTo
Apr 30, 2024Ladenburg Thalmanninit—Buy

About Marker Therapeutics, Inc.

Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens. The company also develops MT-401-OTS for the treatment of acute myeloid leukemia; and MT-601 to treat lymphoma and pancreatic cancer. Marker Therapeutics, Inc. is headquartered in Houston, Texas.

Sector
Healthcare
Industry
Biotechnology
Country
United States

News

Your note

Sign in to keep a note on MRKR — it syncs with the Stock Master app.

Institution ownership

MRKR institution ownership
Holder% heldSharesValueReported
NEA Management Company, LLC12.01%1,071,4283.66MSep 29, 2024
Aisling Capital Management LP3.52%314,2861.07MSep 29, 2024
Vanguard Group Inc2.72%243,122831.48KSep 29, 2024
AR Asset Management, Inc.0.83%73,700252.05KSep 29, 2024
Geode Capital Management, LLC0.80%71,561244.74KSep 29, 2024
Renaissance Technologies, LLC0.45%39,750135.94KSep 29, 2024

Fund ownership

MRKR fund ownership
Holder% heldSharesValueReported
Vanguard Total Stock Market Index Fund1.72%153,473524.88KSep 29, 2024
Vanguard Extended Market Index Fund0.98%87,137298.01KSep 29, 2024
Fidelity Extended Market Index Fund0.45%39,946136.62KOct 30, 2024
iShares Micro Cap ETF0.19%16,57956.70KOct 30, 2024
DFA U.S. Small Cap Series0.18%15,90054.38KJul 30, 2024
Fidelity Total Market Index Fund0.14%12,81143.81KOct 30, 2024
Advertisement